You are here

Alzheimer's Clinical Trials Consortium Selects Elenbecestat and BAN2401 for Upcoming Clinical Studies on Prevention of Alzheimer's Disease

WOODCLIFF LAKE, N.J., May 10, 2019 /PRNewswire/ -- The Alzheimer's Clinical Trials Consortium (ACTC) and Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the investigational oral BACE (beta amyloid cleaving enzyme) inhibitor elenbecestat (development code: E2609) and the investigational anti-amyloid beta (Ab) protofibril antibody BAN2401, which are currently being evaluated as potential treatments for early Alzheimer's disease (AD), have been selected by the ACTC as potential treatments to be evaluated in upcoming clinical studies targeting primary prevention (A3 Study) and secondary prevention (A45 Study) of AD. These studies will be conducted with funding from various sources including the United States National Institute on Aging (NIA), part of the National Institutes of Health, and Eisai.

The ACTC, which is an NIA-funded clinical trial network with 35 primary clinical study sites across the United States, aims to accelerate and expand studies for therapies in AD and related dementias across the spectrum from pre-symptomatic to more severe stages of disease. ACTC was established with grant funding from the NIA in December 2017. The A3 and A45 Studies are led by three academic principal investigators: Dr. Paul Aisen from the University of Southern California, and Drs. Reisa Sperling and Keith Johnson from Brigham and Women's Hospital and Massachusetts General Hospital, Harvard Medical School.

"The A3 and A45 Studies should provide critically important answers about the optimal time to intervene with anti-amyloid therapy, with the hope that starting treatment much earlier in the disease process may be advantageous in preventing future cognitive decline," said Dr. Sperling, Director, Center for Alzheimer Research and Treatment at Brigham and Women's Hospital and co-Principal Investigator, ACTC.

Dr. Aisen, Director of the University of Southern California Alzheimer's Therapeutic Research Institute, which serves as the coordinating center for the ACTC, noted that "The mission of the ACTC includes the development of public-private partnerships to conduct trials of promising candidate therapies. This collaboration with Eisai will allow us to test two promising therapies in innovative studies that may advance the field."

The A3 Study aims to get closer to the goal of primary prevention of AD, through preventing amyloid build-up in the brain. The study targets cognitively normal individuals who are currently below the threshold for amyloid elevation on amyloid PET but are at high risk for further Ab accumulation. The A3 proposed study design will be a global, multicenter, double-blind, randomized trial to compare the effects of two doses of elenbecestat vs. placebo, to test whether a BACE inhibitor can slow brain amyloid accumulation at this very early stage of disease. The A3 Study will also measure accumulation of tangle pathology using tau PET and exploratory cognitive outcomes.

The A45 study will target the preclinical (pre-symptomatic) stage of AD. The study will enroll clinically normal participants (no/minor cognitive impairment) who have elevated levels of amyloid in brain and are at high risk for progression to mild cognitive impairment and AD dementia. The A45 proposed study design will be a global, multicenter, double-blinded, placebo-controlled, randomized trial of a treatment regimen consisting of an anti-Aβ antibody and a BACE inhibitor to prevent cognitive decline and delay biomarkers of pathological progression versus placebo. In the active arm, individuals will be provided first with BAN2401 with the goal to clear amyloid deposits and Aβ protofibrils from the brain, after which they will be maintained on elenbecestat with the aim of decreasing the production of Aβ and preventing the reaccumulation of amyloid plaques and protofibrils.

"We are excited to partner with the ACTC group with trials focusing on therapies for earlier stages of AD and will thus allow us to understand the potential benefit of BAN2401 and elenbecestat across a broader spectrum of the disease," said Lynn Kramer, MD, Chief Clinical Officer and Chief Medical Officer, Neurology Business Group, Eisai.

Trials will be starting early 2020.


Media Inquiries


Public Relations Brigham and Women's Hospital



Lori Schroth

Office: 617-525-6374 | Mobile: 617-459-2111


Public Relations University of Southern California



Leigh Hopper

USC Central Communications

Media Relations Specialist



Libby Holman

Eisai Inc.

201-753-1945 or  

[Notes to editors]

1. About The Alzheimer's Clinical Trials Consortium (ACTC)
The ACTC, funded by the National Institute on Aging at the National Institutes of Health, provides the infrastructure for academic clinical trials in Alzheimer's Disease and related dementias.  The consortium, based at the University of Southern California, Harvard University and the Mayo Clinic, includes expert units to support clinical trials design, biostatistics, informatics, medical safety, regulatory oversight, recruitment, clinical operations, data management, site monitoring, a biomarker laboratory and repository, and neuroimaging.  The ACTC includes 35 primary clinical sites across the United States.

2. About Elenbecestat
Discovered by Eisai, elenbecestat is an investigational oral candidate for the treatment of AD that inhibits BACE. By inhibiting BACE, a key enzyme in the production of Aβ, elenbecestat reduces Aβ production, which reduces amyloid aggregates in the brain. In this regard, elenbecestat is thought to exert disease modifying effects and may have potential to slow the progression of AD. Currently, a global Phase III clinical study program (MISSION AD) of elenbecestat in early AD is underway.

3. About BAN2401
Discovered through a strategic research alliance between Eisai and BioArctic AB (Headquarters: Sweden), BAN2401 is a humanized monoclonal antibody for AD. BAN2401 selectively binds to neutralize and eliminate soluble, toxic Aβ aggregates (protofibril) that are thought to be a causative factor for AD. This suggests that BAN2401 may exert disease modifying effects and may have potential to slow the progression of AD. Currently, a global Phase III clinical study (Clarity AD) of BAN2401 in early AD is underway. Eisai and Biogen Inc. (Nasdaq: BIIB) (Headquarters: Cambridge, Massachusetts, United States) are collaborating on the joint development and commercialization of AD treatments.

4. About Eisai Inc.
Eisai is a leading global research and development-based pharmaceutical company headquartered in Japan, with approximately 10,000 employees worldwide. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. We strive to realize our hhc philosophy by delivering innovative products in therapeutic areas with high unmet medical needs, including Oncology and Neurology. In the spirit of hhc, we take that commitment even further by applying our scientific expertise, clinical capabilities and patient insights to discover and develop innovative solutions that help address society's toughest unmet needs, including neglected tropical diseases and the Sustainable Development Goals.

For more information about Eisai, please visit (for global), (for U.S.) or (for U.K.), and connect with us on Twitter (U.S. and global) and LinkedIn (for U.S.).

Cision View original content:

SOURCE Eisai Inc.